Page 29 - Cll News Today

CLL expert Lori A. Leslie, MD, gives a comprehensive overview of the ALPINE and ELEVATE-RR head-to-head studies of BTK inhibitors in CLL.

Researchers collected physical function measures and blood samples from 24 patients enrolled in a 16-week trial of at-home aerobic and/or resistance exercise.

An April 1 session at the 2023 National Comprehensive Cancer Network (NCCN) on updates in CLL/SLL featured results on the ALPINE study, which led to the January 2023 approval of zanubrutinib in the frontline setting.

CLL experts offer insights on shared decision-making with patients while selecting treatments.

Lori A. Leslie, MD, an expert on chronic lymphocytic leukemia, provides a comprehensive overview of BTK inhibitors used in the treatment of CLL.

A phase 1/1b trial will examine PRGN-3007 in patients with ROR1-positive hematologic and solid cancers.

Hoshiyuki Iida, APN, discusses his role in the multidisciplinary team in the treatment of patients with chronic lymphocytic leukemia.

Lori A. Leslie, MD, and Hoshiyuki Iida, APN, provide an overview of chronic lymphocytic leukemia and the risk stratification process.

Canada Health has approved the fixed-duration, all-oral combination of ibrutinib and venetoclax for the frontline treatment of adult patients with chronic lymphocytic leukemia, including those with 17p deletion.

Learning you have this cancer diagnosis can be especially shocking.